Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope.
MacLachlan, B.J., Dolton, G., Papakyriakou, A., Greenshields-Watson, A., Mason, G.H., Schauenburg, A., Besneux, M., Szomolay, B., Elliott, T., Sewell, A.K., Gallimore, A., Rizkallah, P., Cole, D.K., Godkin, A.(2019) J Biol Chem 294: 20246-20258
- PubMed: 31619516 
- DOI: 10.1074/jbc.RA119.009437
- Primary Citation of Related Structures:  
6HBY - PubMed Abstract: 
CD4 + T-cells recognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), which through peptide-flanking residues (PFRs) can extend beyond the limits of the HLA binding. The role of the PFRs during antigen recognition is not fully understood; however, recent studies have indicated that these regions can influence T-cell receptor (TCR) affinity and pHLA-II stability ...